Irvine, California-based Novus Therapeutics announced that the company’s Phase IIa clinical trial of OPO201 in acute otitis media, or inflammation of the middle ear, failed to meet the primary endpoint.
https://www.pharmalive.com/wp-content/uploads/2020/06/After-Failure-of-Earache-Drug-Novus-Therapeutics-Seeks-Strategic-Alternatives-BioSpace-6-2-20.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2020-06-03 02:47:212020-06-15 18:37:58Novus Seeks Strategic Alternatives After Earache Drug Failure